Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on July 7, 2022, covering events occurring on June 30, 2022. The filing addresses the status of the Chief Financial Officer's employment and the termination of a previously disclosed retirement agreement.
Key Financial Metrics
This filing is a non-financial event report. It does not provide data regarding revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes
- Officer Status Change: Brian G. Drazba, the Chief Financial Officer and Secretary, was originally scheduled to retire on June 30, 2022, pursuant to a Transition and Retirement Agreement.
- Employment Continuation: On June 30, 2022, CEO Daniel P. Gold notified Mr. Drazba that his employment would continue beyond the planned retirement date.
- Agreement Termination: On July 7, 2022, the Company and Mr. Drazba executed a letter agreement terminating the Retirement Agreement. Mr. Drazba will continue under his original 2017 Employment Agreement, subject to potential salary adjustments by the Compensation Committee.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of market risks. The primary contingency addressed is the administrative resolution of the CFO's employment status, ensuring continuity of leadership rather than a departure.
Investor Verification Checklist
- Verify the continued employment of Brian G. Drazba as CFO and Secretary.
- Review the attached Exhibit 10.1 (Retirement Agreement Termination Letter) for specific terms regarding the termination of the retirement plan.
- Monitor future filings for any salary adjustments approved by the Compensation Committee as referenced in the 2017 Employment Agreement.
- Confirm that no other executive departures or appointments are pending, as this filing focuses solely on the reversal of the CFO's retirement.